Actimed Therapeutics successfully closes second tranche of £10m seed financing to progress pipeline for treatment of cancer cachexia and other muscle wasting disorders
January 4, 2023Business Services
London, UK – 4 January 2023. Actimed Therapeutics Ltd, a UK based clinical stage specialty pharmaceutical company focused on bringing …
FDA expands access to abortion pills
January 4, 2023Medical Communications
Following new rules from the FDA under the Biden administration, patients can now obtain the abortion pill mifepristone from retail …
Novartis pays $245m to settle Exforge generic pay-for-delay lawsuit
January 4, 2023Medical Communications
Swiss pharma company Novartis will settle a classic generic pay-for-delay legal battle with direct purchasers, indirect purchasers and retailers regarding …
FDA grants Breakthrough Device Designation for Burning Rock’s multi-cancer detecting test
January 4, 2023Medical Communications
Burning Rock, a Chinese biotech company which focuses on the applications of next-generation sequencing (NGS) technology in the field of …
FDA expected to make decision on controversial Alzheimer’s drug this week
January 4, 2023Medical Communications
The FDA are expected to come to a decision on Eisai and Biogen’s Alzheimer’s drug lecanemab by the end of …
Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia
January 3, 2023Business Services
Milan, Italy, Jan. 3, 2023, 07:00 am CET – Newron Pharmaceuticals S.p.A.
Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
January 3, 2023Business Services
BEERSE, BELGIUM, 3 January 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a …
Cost of over 350 drugs expected to increase in 2023
January 3, 2023Sales and Marketing
With many pharma companies preparing for President Joe Biden’s Inflation Reduction Act (IRA) to begin having an impact, and inflation …
Rare cancer drug for young patients approved
January 3, 2023Research and Development
A new treatment option for adult and paediatric patients with a rare soft tissue cancer has been approved. The FDA …
MediWound receives FDA approval for NexoBrid
January 3, 2023Medical Communications
Israeli biopharma company MediWound has secured FDA approval for its wound care product NexoBrid (anacaulase-bcdb). US-based biopharma company Vericel will …
Datar blood test receives FDA Breakthrough Designation
January 3, 2023Medical Communications
Datar Cancer Genetics has secured FDA Breakthrough Designation for their blood test used to detect inaccessible brain tumours, where traditional …
BioNTech begins phase 1 trial for malaria vaccine
December 23, 2022Medical Communications
BioNTech has announced the start of its new first-in-human phase 1 trial for BNT165b1, a candidate from its programme which …
Celltrion submits application for CT-P13 SC to FDA
December 23, 2022Medical Communications
Celltrion has announced that it has finalised its submission of a biologics license application for the subcutaneous version of a …
Moderna signs ten-year deal with UK Government for vaccine production
December 23, 2022Manufacturing and Production
US biotech company Moderna has finalised a partnership with the UK government to produce vaccines, the main element of which …
COVID-19 antiviral treatment shown to speed up recovery in trial
December 23, 2022Medical Communications
Molnupiravir, made by Merck, Sharp and Dohme (MSD), has been found to reduce the recovery time of COVID-19 patients, however …
Treatment for rare, paediatric growth hormone deficiency recommended by NICE for use on the NHS
December 22, 2022Medical Communications
Walton Oaks, 22 December 2022 – Pfizer Ltd today announces that the National Institute for Health and Care Excellence (NICE) …
AstraZeneca shares two new drug approvals in the EU
December 22, 2022Medical Communications
On Wednesday, AstraZeneca announced two drug approvals in the European Union (EU). The first being Imfinzi’s approval for the treatment …
Everest Medicines and licensing partner Pfizer receive FDA and EMA approval for ulcerative colitis drug
December 22, 2022Medical Communications
Everest Medicines, a biopharmaceutical company, has announced that its licensing partner, Pfizer, has received acceptance from the FDA for a …
New monoclonal antibody for hospitalised COVID-19 patients approved by FDA
December 22, 2022Medical Communications
The FDA has approved Roche’s monoclonal antibody which treats hospitalised adult patients with COVID-19. The antibody, Actemra, is already approved …
Abiomed receives FDA approval for heart pump clinical trial
December 22, 2022Research and Development
Abiomed, a leading provider of medical technology focusing on the circulatory system and oxygenation, has announced that the FDA has …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
